Saturday 17 October 2026
Export MTVA’s income statement to Excel — free account
MetaVia Inc.
MTVA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 68.5% and free cash flow fell 22.4%, each against the same quarter a year earlier.
1.26
0.11
−8.03%
Follow MTVA
MetaVia Inc. (MTVA) P/E ratio
MetaVia Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.4× (August 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.4×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BIVI BioVie Inc. compare | n/m |
| MTVA MetaVia Inc. | n/m |
| LSTA Lisata Therapeutics, Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| VTGN VistaGen Therapeutics, Inc. compare | n/m |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | 0.0× |
| TOVX Theriva Biologics, Inc. compare | 0.1× |
| CSCIF COSCIENS Biopharma Inc. compare | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)